[EN] OXAZOLIDINONE HYDROXAMIC ACID COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS [FR] COMPOSÉS D'ACIDE OXAZOLIDINONE-HYDROXAMIQUE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
[EN] NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS<br/>[FR] NOUVEAUX DÉRIVÉS D'INDOLE UTILES EN TANT QU'AGENTS ANTIDIABÉTIQUES
申请人:MERCK SHARP & DOHME
公开号:WO2014139388A1
公开(公告)日:2014-09-18
Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS
申请人:ACTON, III John J.
公开号:US20160002224A1
公开(公告)日:2016-01-07
Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
[EN] OXAZOLIDINONE HYDROXAMIC ACID COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS D'ACIDE OXAZOLIDINONE-HYDROXAMIQUE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
申请人:NOVARTIS AG
公开号:WO2015066413A1
公开(公告)日:2015-05-07
This invention pertains generally to treating bacterial infections using organic compounds of Formula I. In certain aspects, the invention pertains to treating infections caused by Gram-negative bacteria. (I) wherein X, Y, R1, R2, R3, R4 and R5 and defined herein.
[EN] GPR84 ANTAGONISTS AND USES THEREOF<br/>[FR] ANTAGONISTES DE GPR84 ET LEURS UTILISATIONS
申请人:LIMINAL BIOSCIENCES LTD
公开号:WO2022167457A1
公开(公告)日:2022-08-11
The present invention provides compounds of formula (I), compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.